Key facts
- This page summarizes Simon C. Lowry's Form 4 filing for Emergent BioSolutions Inc. (EBS).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Mar 2026, 21:21.
Simon C. Lowry - 03 Mar 2026 Form 4 Insider Report for Emergent BioSolutions Inc. (EBS)
- Reporting relationship
- SVP, R&D, CMO
- Issuer ticker
- EBS
- Reported as of
- 03 Mar 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Mar 2026, 21:21:35 UTC
- Prior SEC filing
- 16 Dec 2025
- Next SEC filing
- 01 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard S. Lindahl, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Simon C. Lowry filed Form 4 for Emergent BioSolutions Inc. (EBS) on 05 Mar 2026.
Change
- Previous filing in this sequence was filed on 16 Dec 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002044279
Primary reporting owner
Lowry Simon C
- Relationship
- SVP, R&D, CMO
- Address
- 300 PROFESSIONAL DRIVE, GAITHERSBURG
- Signature
- /s/ Richard S. Lindahl, Attorney-in-fact
- Signature date
- 05 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
EBS
transaction
Common Stock
Tax liability
- Transaction value
- Shares
- -10,636
- Change %
- -12%
- Price
- $8.44*
- Shares after
- 77,803
- Date
- 05 Mar 2026
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
EBS
transaction
Derivative
Employee Stock Option (Right to buy)
Award
- Transaction value
- Shares
- +44,834
- Change %
- +44%
- Price
- $0.000000*
- Shares after
- 147,833
- Date
- 03 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 44,834
- Exercise price
- $8.99
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units
Footnote F2
Vests in three equal installments beginning on the day prior to the anniversary date of the grant.